Mineralys Therapeutics (MLYS) Stock Forecast: StockMap's 2-Week Call
MLYS stock forecast: StockMap's model makes no two-week call on Mineralys Therapeutics after the Nov 19 close: its evidence is split, 5 reasons for and 10 against. Right in 4 of 4 two-week windows on MLYS since Sep 15; by chance, a call on the same dates was right 56% of the time.
Mineralys Therapeutics last closed at $14.16, +2.76% on the session.
Against the IVW growth benchmark the position is +5.09% over the forecast window.
Mineralys Therapeutics' market cap is $1.25B as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -15 (too close to call).
Where MLYS sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 5 bullish and 10 bearish.
Agreement across those insights is 67%.
16 daily calls for MLYS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Mineralys Therapeutics in the 15th percentile on return on equity, where 100 is best.
Mineralys Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks Mineralys Therapeutics as the 118th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Mineralys Therapeutics ranks 134th of 394 in the group, against a group median of -0.27.